Plus Therapeutics Faces Nasdaq Delisting Warning
Ticker: PSTV · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2.5 million, $35 million, $500,000, $1,348,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: THTX
TL;DR
Nasdaq says Plus Therapeutics might get kicked off the exchange, needs to boost market cap.
AI Summary
Plus Therapeutics, Inc. announced on September 5, 2024, that it received a deficiency letter from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has 180 days to regain compliance, which may involve increasing its market capitalization.
Why It Matters
This filing indicates a potential risk to the company's stock exchange listing, which could impact its liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company has received a deficiency letter from Nasdaq for failing to meet continued listing requirements, specifically related to market capitalization.
Key Numbers
- 180 days — Compliance Period (Timeframe given by Nasdaq to regain compliance)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing deficiency letter
- September 5, 2024 (date) — Date of deficiency letter
FAQ
What specific listing rule did Plus Therapeutics violate?
The filing indicates a deficiency related to not meeting the minimum market capitalization requirement for continued listing on the Nasdaq Stock Market.
What is the deadline for Plus Therapeutics to regain compliance?
The company has 180 days from the date of the notice, which is September 5, 2024, to regain compliance.
What actions can Plus Therapeutics take to regain compliance?
The company may need to increase its market capitalization to meet Nasdaq's minimum requirements.
What is the potential consequence if Plus Therapeutics fails to regain compliance?
If the company fails to regain compliance within the specified period, its securities may be delisted from the Nasdaq Stock Market.
Has Plus Therapeutics previously faced delisting warnings?
The provided filing does not contain information about previous delisting warnings; it only addresses the current deficiency notice.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-09-06 16:47:29
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 PSTV The Nasdaq Capital Market Ind
- $2.5 million — ule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity (the "Minimum S
- $35 million — a market value of listed securities of $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
- $1,348,000 — 023, disclosed stockholders' equity of ($1,348,000) as of December 31, 2023, and that, as
Filing Documents
- d821033d8k.htm (8-K) — 23KB
- 0001193125-24-215218.txt ( ) — 143KB
- pstv-20240905.xsd (EX-101.SCH) — 3KB
- pstv-20240905_lab.xml (EX-101.LAB) — 18KB
- pstv-20240905_pre.xml (EX-101.PRE) — 11KB
- d821033d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 6, 2024 PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer